Pluristem Therapeutics' (NASDAQ:PSTI) provides an update on the key clinical milestones and corporate developments. The company expects to announce top lin
seekingalpha · 07/21 16:50
Pluristem CEO Issues Shareholder Update On Clinical Programs; Says Had $59M In Cash And Equivalents As Of Jun. 30
HAIFA, Israel, July 21, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products, today issued an update
Benzinga · 07/21 11:14
Pluristem CEO Issues Shareholder Update on Clinical Programs
HAIFA, Israel, July 21, 2020 -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological.
GlobeNewswire · 07/21 11:10
Pluristem files for $250M mixed shelf
Pluristem Therapeutics (NASDAQ:PSTI) has filed a prospectus for a $250M mixed shelf offering. Shares down 1% after-hours.
seekingalpha · 07/17 01:55
Pluristem Therapeutics On July 16 Entered Into Open Market Sale Agreement With Jefferies; May Issue And Sell Common Shares Of Up To $75M From Time To Time Through Jefferies
-Reuters
Reuters · 07/16 21:31
Pluristem Therapeutics Inc Files For Mixed Shelf Of Up To $250M
-Reuters
Reuters · 07/16 20:57
Stocks To Watch: Postmates, Walgreens And Cannabis Plays
Seeking Alpha - Article · 07/04 12:17
Pluristem Is a High Risk, High Reward Play, Says Jefferies Analyst
Just how high can Pluristem Therapeutics (PSTI) climb? The Israeli biotech has outperformed in 2020, with shares up by 94% year-to-date. Driving the micro-cap’s forward charge has been a familiar 2020 narrative. The company’s PLX-PAD cell therapy, which uses a